New Myelodysplastic Syndromes Findings from Institute of Hematology and Blood Diseases Hospital Published [Upfront Allogeneic Hematopoietic Stem Cell Transplantation Can Provide Survival Benefit Versus Hypomethylating Agent in Myelodysplastic ...]

MLA

“New Myelodysplastic Syndromes Findings from Institute of Hematology and Blood Diseases Hospital Published [Upfront Allogeneic Hematopoietic Stem Cell Transplantation Can Provide Survival Benefit Versus Hypomethylating Agent in Myelodysplastic ...].” Stem Cell Week, Dec. 2023, p. 587. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.776559287&authtype=sso&custid=ns315887.

APA

New Myelodysplastic Syndromes Findings from Institute of Hematology and Blood Diseases Hospital Published [Upfront Allogeneic Hematopoietic Stem Cell Transplantation Can Provide Survival Benefit Versus Hypomethylating Agent in Myelodysplastic ...]. (2023, December 18). Stem Cell Week, 587.

Chicago

Stem Cell Week. 2023. “New Myelodysplastic Syndromes Findings from Institute of Hematology and Blood Diseases Hospital Published [Upfront Allogeneic Hematopoietic Stem Cell Transplantation Can Provide Survival Benefit Versus Hypomethylating Agent in Myelodysplastic ...],” December 18. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.776559287&authtype=sso&custid=ns315887.